GLP-1 medications do far more than help you lose weight. Research from major clinical trials shows they improve heart outcomes, protect kidneys, reverse liver damage, reduce sleep apnea severity, ease joint pain, and may guard against cognitive decline — often through anti-inflammatory mechanisms partly independent of weight loss itself.
Semaglutide and tirzepatide launched as blood sugar medications. They became household names for weight loss. But the clinical trial data from the last few years paints a much bigger picture. Here are seven benefits the research now supports — and what each one means if you're considering a GLP-1 protocol.
1. Reduced Risk of Heart Attack and Stroke
The SELECT trial enrolled 17,604 people with obesity and established cardiovascular disease. Subcutaneous semaglutide cut the risk of major adverse cardiovascular events — heart attack, stroke, or cardiovascular death — by 20% versus placebo over 34 months. Crucially, much of that benefit appeared independent of how much weight participants lost.
In January 2025, the FDA expanded semaglutide's approved indications specifically to include reducing cardiovascular risk in adults with obesity or overweight. For patients who need GLP-1 therapy and have cardiovascular risk factors, this isn't a side benefit. It's now a listed indication.
2. Slower Kidney Disease Progression
The FLOW trial followed 3,533 adults with type 2 diabetes and chronic kidney disease for 3.4 years. Semaglutide reduced the composite kidney endpoint — kidney failure, sustained loss of kidney function, or kidney-related death — by 24%. The FDA expanded semaglutide's label to include kidney disease progression in early 2025 based on these findings.
GLP-1 receptors exist in kidney tissue. The mechanism likely involves both direct anti-inflammatory effects on renal cells and downstream benefits from improved blood sugar and blood pressure control.
3. Liver Disease Reversal (MASH/MASLD)
Metabolic dysfunction-associated steatohepatitis (MASH) is a serious form of fatty liver disease. In the 240-week ESSENCE trial, semaglutide 2.4 mg weekly resolved steatohepatitis in 63% of participants versus 34% on placebo at the 72-week mark. Tirzepatide showed similar results — resolution rates up to 62% versus 10% for placebo in a phase 2 trial.
Hepatocytes don't express the GLP-1 receptor directly. The liver benefits likely reflect reduced visceral fat, improved metabolic signaling, and systemic inflammation reduction — all downstream of GLP-1 activity.
4. Clinically Meaningful Sleep Apnea Improvement
In 2024, tirzepatide became the first weight-loss medication approved for obstructive sleep apnea (OSA). The SURMOUNT-OSA trials showed tirzepatide reduced the apnea-hypopnea index (how many breathing interruptions per hour) by 25–29 events per hour versus just 5 events per hour with placebo — a clinically significant difference that allowed many participants to reduce or eliminate PAP therapy.
This matters because OSA is associated with elevated cardiovascular risk, metabolic disruption, and impaired sleep quality. Treating obesity-related OSA with GLP-1 therapy addresses both conditions simultaneously.
5. Reduced Osteoarthritis Pain
The STEP 9 trial tested semaglutide in 407 people with knee osteoarthritis and obesity. The WOMAC pain score (higher = more pain) dropped by 41.7 points with semaglutide versus 27.5 points on placebo. Both weight loss and direct anti-inflammatory effects of GLP-1 on joint tissue are thought to contribute.
For people on a GLP-1 protocol who also have joint pain, this is meaningful: the medication may improve functional mobility as a secondary benefit. This doesn't replace physical therapy or orthopedic evaluation, but it's a real added benefit.
6. Neuroprotection and Cognitive Health
Multiple cardiovascular outcome trials — SELECT, SUSTAIN-6, REWIND, PIONEER 6 — show GLP-1 medications reduce stroke incidence. Beyond stroke, emerging data links GLP-1 use to lower risk of all-cause dementia and Alzheimer's disease in people with type 2 diabetes. The EVOKE and EVOKE+ trials are actively testing oral semaglutide in early Alzheimer's, with results expected in 2025–2026.
GLP-1 receptors are found in the central nervous system. The mechanisms may include reduced neuroinflammation, modulation of platelet aggregation, and protection of vascular integrity in the brain.
7. Improved Peripheral Arterial Blood Flow
Peripheral artery disease (PAD) causes reduced blood flow to the limbs, leading to pain and limited walking ability. The STRIDE trial showed semaglutide 1 mg weekly significantly increased maximum walking distance in people with PAD and type 2 diabetes over 52 weeks — with modest weight loss (around 4 kg) suggesting the benefit isn't purely weight-mediated.
For patients with PAD, improved walking capacity is a direct functional outcome. This places GLP-1 therapy in a genuinely multi-system role for metabolic and vascular health.
How GLP-1 Medications Produce These Benefits
The unifying mechanism appears to be systemic inflammation reduction. GLP-1 medicines consistently lower biomarkers including CRP, TNF-α, IL-6, and MCP-1 across clinical trials. These effects occur through at least three pathways:
- Direct activation of GLP-1 receptors in heart, kidney, liver, joint, and immune cells
- Indirect effects via improved blood sugar control and reduced body fat
- Central nervous system signaling through GLP-1R neurons that dampen peripheral inflammatory responses
Some of these benefits are partly independent of weight loss — the SELECT trial specifically noted the cardiovascular benefit was not proportional to the degree of weight lost. This changes how we should think about GLP-1 therapy: not just as a weight-loss tool, but as a cardiometabolic intervention.
What This Means for Your Protocol
Understanding how GLP-1 works helps set appropriate expectations. These medications are compounded and not FDA-approved for all of the indications listed above — some applications are still investigational or off-label. Any GLP-1 protocol requires subject to medical approval by a licensed provider and individualized evaluation. Compounded semaglutide and tirzepatide are not FDA-approved products.
If you're already managing cardiovascular risk, kidney disease, fatty liver, or sleep apnea alongside a weight goal, discuss those conditions during your asynchronous evaluation at TelosRX. Your provider can consider the full clinical picture when determining whether a GLP-1 protocol is appropriate for you.
| Benefit | Key Trial | Primary Finding | Evidence Level |
|---|---|---|---|
| Cardiovascular risk | SELECT (semaglutide) | 20% reduction in MACE events | Phase 3 RCT, FDA-approved indication |
| Kidney disease | FLOW (semaglutide) | 24% reduction in composite kidney endpoint | Phase 3 RCT, FDA-approved indication |
| Liver disease (MASH) | ESSENCE (semaglutide) | 63% vs 34% steatohepatitis resolution | Phase 3 RCT |
| Sleep apnea | SURMOUNT-OSA (tirzepatide) | 25–29 event/hr AHI reduction | Phase 3 RCT, FDA-approved indication |
| Osteoarthritis pain | STEP 9 (semaglutide) | −41.7 vs −27.5 WOMAC pain score | Phase 3 RCT |
| Neuroprotection | EVOKE/EVOKE+ (ongoing) | Lower dementia risk in observational data | Ongoing Phase 3; observational evidence |
| Peripheral artery disease | STRIDE (semaglutide) | Significantly greater walking distance | Phase 3 RCT |
See the full clinical trial data at PMC — "The Expanding Benefits of GLP-1 Medicines" (Cell Reports Medicine, 2025) and the FLOW trial (NEJM, 2024). The SURMOUNT-OSA results are available at NEJM, 2024.
Already on a GLP-1 protocol? Read how compounded tirzepatide is accessed through telehealth in 2026 for more context on what providers consider during evaluation.
Frequently Asked Questions
Do GLP-1 drugs help the heart beyond just weight loss?
Yes. The SELECT trial showed semaglutide reduced major cardiovascular events by 20% in people with obesity and established cardiovascular disease. The benefit was partly independent of how much weight participants lost, suggesting GLP-1 has direct anti-inflammatory and vascular effects. The FDA approved semaglutide for cardiovascular risk reduction in 2024.
Can GLP-1 medications improve kidney disease?
Clinical evidence supports this. The FLOW trial found semaglutide reduced the composite kidney failure endpoint by 24% in people with type 2 diabetes and chronic kidney disease. The FDA expanded semaglutide's indications to include CKD progression in early 2025. Any treatment should be under licensed provider supervision, and individual eligibility varies.
Does semaglutide help fatty liver disease?
Phase 3 data shows semaglutide resolved metabolic steatohepatitis (MASH) in 63% of participants versus 34% on placebo at 72 weeks. Tirzepatide showed similar results in a separate phase 2 trial. These medications are not currently FDA-approved specifically for MASH but are being actively studied in longer-term trials.
Can GLP-1 drugs help with sleep apnea?
Tirzepatide received FDA approval for obstructive sleep apnea with obesity in 2024. The SURMOUNT-OSA trials showed it reduced breathing interruptions during sleep by roughly 25–29 events per hour versus about 5 events per hour for placebo. This is a clinically meaningful improvement for many patients.
Are GLP-1 benefits independent of weight loss?
Some appear to be. The SELECT cardiovascular trial specifically noted that the 20% MACE reduction was not proportional to the extent of weight loss. GLP-1 medicines reduce inflammatory biomarkers including CRP, TNF-α, and IL-6 through direct receptor activation in organs, not only through fat reduction.
What GLP-1 medications are approved for cardiovascular protection?
Subcutaneous semaglutide (brand name Wegovy) holds FDA approval for reducing cardiovascular risk in adults with obesity or overweight and established cardiovascular disease. Compounded semaglutide is not FDA-approved and is prepared under federal compounding regulations. Provider evaluation is required before any GLP-1 protocol.
How does GLP-1 reduce inflammation?
GLP-1 medicines reduce inflammation through at least three pathways: direct activation of GLP-1 receptors in heart, kidney, liver, joint, and immune cells; indirect effects via improved metabolic control; and central nervous system signaling through GLP-1R neurons that suppress peripheral inflammatory responses. Biomarkers like CRP and IL-6 consistently fall in clinical trials.
Are compounded GLP-1 medications available for these benefits?
Compounded semaglutide and tirzepatide are prepared under federal compounding regulations and are not FDA-approved. They require individual evaluation and a provider-issued prescription. TelosRX operates as an asynchronous telehealth service — your evaluation is reviewed by a licensed provider. Approval is not guaranteed and individual results vary.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.